Compugen, Merck Serono tackle peptide for inflammation

Compugen Ltd. announced recently a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, which covers CGEN-855, a Compugen-discovered novel peptide targeting the FPRL1 G-protein coupled receptor (GPCR).

Amy Swinderman
TEL AVIV, Israel—Compugen Ltd. announced recently a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, which covers CGEN-855, a Compugen-discovered novel peptide targeting the FPRL1 G-protein coupled receptor (GPCR). This peptide has demonstrated, in recently completed initial in vitro and in vivo studies, the potential to treat, among other indications, inflammatory diseases.

The agreement covers additional research to be conducted by Compugen and provides Merck Serono with an option to exclusively license the novel peptide for worldwide development and commercialization.

"We are very proud to add Merck Serono to the growing list of leading pharma companies with which we have collaborations for the advancement of our product candidates," said Compugen CEO Mr. Alex Kotzer. "We are also pleased to be the first Israeli biotech company that has signed an agreement with Merck Serono under the Global Enterprise Partnership program of the Chief Scientist of Israel." DDN

Amy Swinderman

Published In:


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022